Nuvama Initiates Coverage on Neuland Laboratories
About Neuland Laboratories: Neuland Laboratories Limited is a leading Indian pharmaceutical company specializing in active pharmaceutical ingredients (APIs) and peptides. The company serves global markets, offering high-quality APIs for regulated markets. Its focus on research, peptide facility expansion, and regulatory compliance positions it as a growth-oriented pharmaceutical player.
Nuvama Coverage Highlights
- Coverage initiated with Buy recommendation; target price ₹17,700.
- Peptides expected to drive growth post-FY28E.
- Unit III expansion is a key growth lever till FY28E.
- Revenue projected to grow 1.8x from FY25-28E; CMS share ~64%.
- Pipeline and peptide facility to support growth beyond FY28E.
- Growth pick-up expected from H2FY26E.
- FY25-28E CAGR: Revenue 21%, EBITDA 37%, PAT 45%.
- Valuations at 39x/33x FY27E/FY28E EPS.
Investor Takeaway
Neuland Labs is positioned for strong growth with peptide facility expansion and a robust API pipeline. Investors may look at it as a long-term growth opportunity in the pharmaceutical sector, with key growth expected post-FY28E.
Trade Tips: Nifty Tip | BankNifty Tip
Read free content at Indian-Share-Tips.com, a SEBI Registered Advisory Services.
SEBI Disclaimer: The information provided in this post is for informational purposes only and should not be construed as investment advice. Readers must perform their own due diligence and consult a registered investment advisor before making any investment decisions. The views expressed are general in nature and may not suit individual investment objectives or financial situations.
Written by Indian-Share-Tips.com, which is a SEBI Registered Advisory Services
